Bevacizumab

Generic Name: Bevacizumab

Brand Names: Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi

Drug Type: Biotech

Chemical Formula: -

CAS Number: 216974-75-3

Unique Ingredient Identifier: 2S9ZZM9Q9V

Background: There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...

Indication: As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...

Associated Conditions: Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Associated Therapies: First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment

Clinical Trials

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Phase 2

Recruiting

Conditions: Colorectal Cancer
Liver Metastases

Interventions: Drug: Oxaliplatin
Drug: Fluorouracil
Drug: Serplulimab
Drug: Bevacizumab

First Posted Date: 2024-02-28

Last Posted Date: 2024-03-04

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 156

Registration Number: NCT06280495

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Adebrelimab
Drug: Oxaliplatin
Drug: Capecitabine
Drug: Bevacizumab

First Posted Date: 2024-02-28

Last Posted Date: 2024-02-28

Lead Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Target Recruit Count: 36

Registration Number: NCT06282445

Locations: 🇨🇳
The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua, Zhejiang, China

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Phase 2

Recruiting

Conditions: Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)

Interventions: Drug: Trastuzumab deruxtecan
Drug: Bevacizumab

First Posted Date: 2024-02-22

Last Posted Date: 2024-11-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 175

Registration Number: NCT06271837

Locations: 🇨🇳
Research Site, Zhengzhou, China

Efficacy and Safety of Anti-angiogenic Therapy with IV Bevacizumab in Patients with Symptomatic Cerebral Arteriovenous Malformations

Phase 2

Not yet recruiting

Conditions: Cerebral AV Malformation

Interventions: Drug: Bevacizumab
Drug: Placebo

First Posted Date: 2024-02-20

Last Posted Date: 2024-11-21

Lead Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

Target Recruit Count: 54

Registration Number: NCT06264531

Botensilimab and Balstilimab Optimization in Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Botensilimab
Drug: Balstilimab
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil
Drug: Bevacizumab
Drug: Panitumumab

First Posted Date: 2024-02-20

Last Posted Date: 2024-11-20

Lead Sponsor: Nicholas DeVito, MD

Target Recruit Count: 15

Registration Number: NCT06268015

Locations: 🇺🇸
Duke University, Durham, North Carolina, United States

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Not Applicable

Recruiting

Conditions: Hepatocellular Carcinoma
Liver Cancer Stage IV
Bevacizumab
Cryoablation
Cadonilimab
Pulmonary Metastases

Interventions: Drug: Cadonilimab
Drug: Bevacizumab
Procedure: Cryoablation

First Posted Date: 2024-02-20

Last Posted Date: 2024-02-20

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 80

Registration Number: NCT06265350

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Phase 3

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: FOLFIRI Regimen
Drug: Sotorasib
Drug: Bevacizumab-awwb
Drug: Panitumumab

First Posted Date: 2024-02-12

Last Posted Date: 2024-12-19

Lead Sponsor: Amgen

Target Recruit Count: 450

Registration Number: NCT06252649

Locations: 🇺🇸
Orchard Healthcare Research Inc, Skokie, Illinois, United States
🇺🇸
Pikeville Medical Center, Pikeville, Kentucky, United States
🇺🇸
Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States

and more 82 locations